Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06948435 · ClinicalTrials.gov registry record · Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
A Phase 3 study of Hypertension and Overweight or Obesity, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 487
- Enrollment target
- 20
- Study locations
NCT06948435 is a Phase 3 study of Hypertension and Overweight or Obesity that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 487 participants, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT06948435, a Phase 3 study of Hypertension and Overweight or Obesity, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 487 participants
- Enrollment target
- 20
- Study locations
Study Summary
GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Orforglipron
Study Locations (20)
Florida
- Excel Medical Clinical Trials - Boca Raton
- Care Access - Brandon - Brandon
- Northeast Research Institute - Downtown Office - Jacksonville
- Peace River Cardiovascular Center - Port Charlotte
California
- Valley Clinical Trials, Inc. - Covina
- Valley Clinical Trials, Inc. - Northridge
Nevada
- Excel Clinical Research, LLC - Las Vegas
- Palm Research Center Sunset - Las Vegas
Ohio
- Remington-Davis, Inc - Columbus
- PriMED Clinical Research - Dayton
Arizona
- Elite Clinical Studies, LLC - Phoenix
Connecticut
- Chase Medical Research, LLC - Waterbury
Hawaii
- East-West Medical Research Institute - Honolulu
Maryland
- Ascension Saint Agnes Heart Care - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 487 participants |
| Start Date | 2025-04-30 |
| Est. Completion | 2027-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06948435
The ClinicalTrials.gov registry entry for NCT06948435 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 487 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (86% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06948435 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, California, Nevada.
Frequently Asked Questions
What is clinical trial NCT06948435 about?
NCT06948435 is a clinical study titled "A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1". GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
What is the current status of trial NCT06948435?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 487 participants. The study started on 2025-04-30. Estimated completion is 2027-09.
What conditions does trial NCT06948435 study?
This clinical trial studies the following conditions: Hypertension, Overweight or Obesity.
What interventions are being tested in trial NCT06948435?
The interventions under investigation include: Placebo (DRUG), Orforglipron (DRUG).
Who is sponsoring clinical trial NCT06948435?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06948435 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
-
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.